What is the recommended management for a woman over 50 with chronic gastro‑esophageal reflux disease, a hiatal hernia, and elevated body‑mass index?

Management of Chronic GERD with Hiatal Hernia in Women Over 50 with Elevated BMI

Women over 50 with chronic GERD, hiatal hernia, and elevated BMI should pursue weight loss of at least 10% of body weight as the primary therapeutic intervention, combined with PPI therapy during the weight loss period, and if symptoms remain refractory or if they are candidates for long-term PPI therapy, should undergo objective testing with endoscopy and prolonged wireless pH monitoring to guide definitive management—with Roux-en-Y gastric bypass being the preferred surgical option if bariatric surgery is indicated, rather than fundoplication alone. 1, 2

Algorithmic Management Approach

Step 1: Weight Loss as Primary Intervention

• Target: ≥10% body weight reduction 1
• This is Grade A, BEL 1 evidence specifically for GERD in patients with elevated BMI
• Weight loss of 10% can reduce symptoms, decrease PPI use, and in some cases allow complete discontinuation of acid suppression 3
• Implement structured lifestyle intervention with:
  • Personalized hypocaloric diet
  • Aerobic exercise program
  • Behavioral modifications 1

Step 2: Concurrent PPI Therapy During Weight Loss

• Initiate or continue PPI therapy while pursuing weight loss 1
• Start with once-daily dosing for 4-8 weeks 2
• If inadequate response, escalate to twice-daily dosing or switch to more potent acid suppressive agent 2
• This addresses symptoms during the weight loss period, which takes time to achieve therapeutic effect

Step 3: Objective Testing for Long-Term Management Planning

Since this patient has chronic GERD and will likely require long-term therapy, objective testing should be performed 2:

• Upper endoscopy to:

  • Assess for erosive esophagitis (LA grade B or greater)
  • Screen for Barrett's esophagus (women over 50 with chronic GERD meet screening criteria)
  • Evaluate hiatal hernia size 2

• If no erosive disease or Barrett's found: Perform 96-hour wireless pH monitoring off PPI (preferred if available) to:

  • Confirm pathologic GERD
  • Phenotype the reflux pattern
  • Guide long-term management decisions 2

Step 4: Surgical Decision-Making Based on Findings

Critical distinction for this patient population:

If bariatric surgery is indicated (BMI ≥35 with comorbidities or ≥40):

• Roux-en-Y gastric bypass is the procedure of choice 1
• This is Grade B, BEL 2 evidence specifically for patients with obesity AND moderate-to-severe GERD, hiatal hernia, esophagitis, or Barrett's esophagus
• Gastric bypass addresses both obesity and GERD simultaneously
• Superior to fundoplication in this population because it induces sustained weight loss and treats obesity-related comorbidities 4, 5
• Avoid sleeve gastrectomy and intragastric balloon as these can worsen GERD 1

If BMI does not meet bariatric surgery criteria but symptoms remain refractory:

• Laparoscopic fundoplication with hiatal hernia repair 6, 7
• However, be aware that fundoplication outcomes worsen with increasing BMI 4
• Consider magnetic sphincter augmentation as minimally invasive alternative 6

Step 5: Titration and Long-Term Management

If weight loss successful and symptoms improve:

• Attempt PPI de-escalation to lowest effective dose 2
• Can potentially discontinue PPI entirely if ≥10% weight loss achieved and no erosive disease or Barrett's present 3
• 27/50 patients (54%) in one study completely discontinued PPI after achieving 10% weight loss 3

If erosive esophagitis or Barrett's esophagus present:

• Long-term PPI therapy required regardless of weight loss success 2
• Cannot safely discontinue acid suppression in these patients

Key Clinical Pitfalls to Avoid

1. Don't perform fundoplication alone in patients with obesity and GERD: This addresses only the reflux mechanism but not the underlying obesity driving the disease, leading to higher recurrence rates 4, 5

2. Don't skip objective testing in chronic GERD: The 12-month rule applies—if PPI therapy continues beyond 12 months without proven GERD, endoscopy and pH monitoring should be offered 2

3. Don't assume all reflux symptoms are acid-related: Prolonged wireless pH monitoring (96-hour preferred) off PPI is essential to confirm pathologic acid exposure versus functional esophageal disorder 2

4. Don't underestimate the therapeutic effect of weight loss: This is often more effective than medication escalation and addresses the root cause 1, 3

5. Age matters for hiatal hernia: Older patients (like this woman over 50) show statistically significant association between age and larger hiatal hernias, higher DeMeester scores, and symptom correlation 8

Evidence Strength Considerations

The recommendation prioritizes the 2022 AGA guideline 2 for GERD management framework and the 2016 AACE/ACE obesity guideline 1 for the specific weight loss targets and surgical approach in obese patients with GERD. The convergence of these two high-quality guidelines provides clear direction: weight loss is not optional lifestyle advice but a Grade A therapeutic intervention with specific targets (≥10%), and surgical approach must account for both conditions simultaneously.

The 2025 research 6 confirms that Roux-en-Y gastric bypass remains gold standard for this specific population, though it appropriately notes fundoplication remains standard for non-obese GERD patients.